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Abstract
Background: Pattern Recognition techniques can provide invaluable insights in the field of neuro-oncology. This is because
the clinical analysis of brain tumors requires the use of non-invasive methods that generate complex data in electronic
format. Magnetic Resonance (MR), in the modalities of spectroscopy (MRS) and spectroscopic imaging (MRSI), has been
widely applied to this purpose. The heterogeneity of the tissue in the brain volumes analyzed by MR remains a challenge in
terms of pathological area delimitation.
Methodology/Principal Findings: A pre-clinical study was carried out using seven brain tumor-bearing mice. Imaging and
spectroscopy information was acquired from the brain tissue. A methodology is proposed to extract tissue type-specific
sources from these signals by applying Convex Non-negative Matrix Factorization (Convex-NMF). Its suitability for the
delimitation of pathological brain area from MRSI is experimentally confirmed by comparing the images obtained with its
application to selected target regions, and to the gold standard of registered histopathology data. The former showed good
accuracy for the solid tumor region (proliferation index (PI).30%). The latter yielded (i) high sensitivity and specificity in
most cases, (ii) acquisition conditions for safe thresholds in tumor and non-tumor regions (PI.30% for solid tumoral region;
#5% for non-tumor), and (iii) fairly good results when borderline pixels were considered.
Conclusions/Significance: The unsupervised nature of Convex-NMF, which does not use prior information regarding the
tumor area for its delimitation, places this approach one step ahead of classical label-requiring supervised methods for
discrimination between tissue types, minimizing the negative effect of using mislabeled voxels. Convex-NMF also relaxes
the non-negativity constraints on the observed data, which allows for a natural representation of the MRSI signal. This
should help radiologists to accurately tackle one of the main sources of uncertainty in the clinical management of brain
tumors, which is the difficulty of appropriately delimiting the pathological area.
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Introduction
Nuclear magnetic resonance (MR) is a key technique for the
non-invasive analysis of brain tumors in the field of neuro-
oncology. The spectroscopic variant of MR, Magnetic Resonance
Spectroscopy (MRS), provides radiologists with a precise meta-
bolic signature of the target tissue, allowing the identification of a
wide array of molecules that may be present in tissues, even at low
concentration (mM range).
Magnetic Resonance Spectroscopic Imaging (MRSI) combines
both spectroscopic and imaging acquisition modalities to produce
spatially localized spectra, and thus delivers information about the
spatial localization of molecules. This modality has been success-
fully applied to monitoring the metabolic heterogeneity of human
brain tumors [1–4].
The rich information contained in MR signals makes them
ideally suited to the application of pattern recognition (PR)
techniques [5,6]. Over the last two decades, these techniques have
been successfully applied to the problem of knowledge extraction
from human brain tumor data, for diagnosis and prognosis of
different pathologies, mostly using single-voxel proton MRS (SV
1H-MRS) [7–12].
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Even when substantial advances have been achieved in the
application of PR to the problems of brain tumor type and grade
discrimination, a ‘‘gray zone’’ of uncertainty in tissue character-
ization still remains, where spectra of different tissue types mix. To
address this limitation, methods that provide accurate discrimina-
tion of tissue types from the MR spectra, with support from MR
images, would be required, ideally without the need for prior
information regarding tumor type and grade. This, from the PR
viewpoint, is an unsupervised modeling task.
As an example of the need for such methods, for instance for the
problem of discriminating normal from abnormal tissue, figure 1
illustrates that no single metabolite image produces, by itself, a
consistent segmentation. This figure compiles six 10610 color-
coded maps displaying the spatial accumulation of the main
metabolites detected by MRSI in a mouse model of brain tumor
(choline, N-acetyl aspartate (NAA), lactate, lipids, creatine, and
alanine), superimposed over the T2 weighted (T2-W) MR image
[13]. More sophisticated approaches for metabolite imaging have
been proposed, for example using selected metabolite concentra-
tion estimates and exploiting spatial information to improve tissue
heterogeneity definition [14], but, as in figure 1, fully consistent
segmentation using a single metabolite concentration does not
seem evident and varies in quality with tumor type in the three
patients investigated.
In the past, the problem has been mostly undertaken from a
supervised point of view, through the so-called nosologic imaging
approach, in which an image obtained with PR is color-coded
according to its histopathological class [3,15] or according to an
index of ‘‘metabolic abnormality’’ above a certain threshold, e.g.
the choline-containing compound - NAA index (CNI) [4,16].
In the current study, we approach this problem using signal
source extraction techniques. By considering spectra from a grid of
voxels (a small cubic based volume element (voxel) for the region
to be sampled with MRS) in a region of the brain (also known as
volume of interest, VOI), we aim to separate the constituent source
signals on the assumption that they are mixed linearly in each
single-voxel spectral measurement. This is a fair assumption, given
that in vivo spectroscopy signals are the result of overlapping peaks,
caused by broad resonances [17] as opposed to narrow peaks that
are characteristic of high-resolution spectra of compounds in
solution. Through source extraction, if there were different
constituent tissue types present in these heterogeneous areas of
the brain they might be separately identified and quantified. As a
result, the level of tissue type (class) assignment for the sources of
each voxel spectrum could also be quantified. This provides us
with an unsupervised class assignment alternative to the standard
supervised classification of a complete spectrum.
Importantly, this methodology does not involve combining
spectra from different subjects, thus focusing on intra-subject
variation without contamination from inter-subject overlaps.
We propose the use of an unsupervised method for matrix
factorization, specifically the convex [18] variant of Non-negative
Matrix Factorization (NMF, [19,20]), for the extraction of the
sources underlying the MRS signal, the identification of tumor
type-specific sources, and the generation of image maps providing
an adequate delimitation of the pathological area.
Different variants of NMF have previously been applied in the
context of neuro-oncology to distinguish normal from abnormal
masses, such as the one proposed by Lee and Seung [20], used in
[21], and the constraint NMF (cNMF) technique used in [22] and
[23]. Unlike the Convex-NMF technique [18] used in our study,
both variants require the source and mixing matrices to be non-
negative. This is an important advantage of Convex-NMF, given
that the analyzed MRSI data can take negative values. Previous
attempts of using NMF on similar data have resorted to either
extra-long echo time (TE) spectra at 280 ms [23], or magnitude
spectra [21], both of which render only positive peaks.
In [21], authors decomposed the observed spectra of multiple
voxels into what they called abundance distributions and
constituent spectra. The accuracy of the estimated abundances
was validated on phantom data, i.e. synthetic samples of known
composition, while the extracted spectra were validated with their
correlation with MRS data from 20 patients, on the choline and
NAA peak areas. In [22], synthetic and real MRS data were used
to calculate the error between the extracted sources and the
observed spectra; and in [23], in vivo MRS and MRI data were
used to evaluate the results.
For the current paper, a pre-clinical study was carried out using
brain tumor-bearing mice. In vivo MRI and MRS were acquired
from the brain and tumor tissue, along with ex vivo postmortem
histology slides of the same animals. This enabled us not only to
evaluate the correlation of the sources obtained with the observed
spectra, but also to evaluate how accurate the calculated maps
were in delineating the tumor region, with respect to a true
biological correlate acquired ex vivo, upon sacrifice of the animal.
This ex vivo – in vivo correlation is virtually impossible to achieve
with human brain tumors.
In summary, the aims of the experiments carried out for this
study were to: 1) Explore the comparative ability of NMF methods
to extract the constituent sources of MRSI data; 2) Generate tissue
labels in a fully unsupervised mode; and 3) Investigate the
possibility of creating an accurate delimitation of the tumor area,
after identifying the sources that describe the tumor tissue. This
technique is unsupervised in the sense that labels (tumor or normal
tissue) are not required to create a model of the analyzed MRSI
data, i.e. to find the MRS sources. This is important since routine
histopathological assignment of the class and grade of specific
tumors has been shown not to be fully reproducible [24–26] and
may introduce unwanted variation in the supervised analysis.
Materials and Methods
Ethics Statement
All studies were approved by the local ethics committee (Comissio´
d’E`tica en l’Experimentacio´ Animal i Humana (CEEAH). Available:
http://www.recerca.uab.es/ceeah. Accessed 17 May 2012.),
according to the regional and state legislation (protocol DARP-
3255/CEEAH-530). Mice were obtained from Charles River
Laboratories (France) and housed at the animal facility of the
Universitat Auto`noma de Barcelona (Servei d’Estabulari) [27].
Materials: Description of the Data
Glioblastoma multiforme (GBM) is a malignant intra-cranial
tumor, of high incidence and very poor prognosis in humans.
Seven GL261 GBM-bearing mice [27] were scanned at 7 Tesla by
PRESS-MRSI, using two different echo times: short, 12 ms (STE);
and long, 136 ms (LTE). Compared to LTE, STE spectra typically
show more complex patterns, including signals from metabolites
with short and long T2 relaxation times. In LTE spectra, signals
with short T2 will be lost, such as most lipids and macromolecules,
remaining visible only spins with longer T2, i.e. small metabolites.
Thus, the lactate methyl signals resonating close to the lipid methyl
groups become more visible in LTE spectra. In addition, due to J-
coupling effects, the methyl protons of alanine and lactate will
appear inverted in LTE spectra, that is, they will undergo a 180
degree phase shift compared to other visible metabolites [15].
Six of these mice, namely C69, C71, C32, C179, C233, and
C234, were described in [27]. A seventh mouse, namely C278,
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was used in this work to increase the number of experiments. This
animal was handled (tumor induction) and scanned exactly as
reported for the other six. The PRESS MRSI data grid was
formed by an array (10610 voxels) with an in-plane resolution of
0.5560.55 mm and a 1 mm slice thickness in the 3rd dimension
[27]. This volume of interest was manually positioned approxi-
mately in the center of the brain, based on the reference image, in
a way that it would include most of the tumor mass and also part
of the normal/peritumoral brain parenchyma.
Sources extracted as described later on in this section were used to
create maps delimiting the tumor region. These maps were compared
to the gold standard, which, in this study, is Ki67 stained sections of
the post-mortem, paraffin-embedded mice brains as in [28].
Ki67 immunostaining allows the spatial determination of the
proliferating population of cells in an individual tumor [29]. The
proliferation index (PI), also called mitotic index, was calculated
for each tumor by, first, immunohistochemical technique on
paraffin-embedded slices with the Ki-67 antibody (BD Biosciences
Pharmingen 550609) and, second, subsequently counting the
number of positive cells per field at 406magnification. This was
achieved with the Definiens Developer XD 1.2 software (Definiens
website. Available: http://www.definiens.com. Accessed 17 May
2012.) ‘‘Image Registration: MRI & Tissue Slide’’ package, which
correlates the MRI with the corresponding Ki-67 immunostained
slice through an affine transformation. The Ki67 immunostained
slice that best matched the MRI slice was chosen by the
pathologist (co-author, M. Pumarola) following anatomical
criteria. In this particular murine model, and according to the
pathologist, PI.30% would correspond to a safe threshold for the
solid tumoral region, whereas a PI#5% would correspond to
definitely non-tumor (excluding reactive gliosis and other phe-
nomena), in agreement with similar studies (PI,12% for control)
[30]. In humans, the PI values for glioblastomas vary considerably,
reflecting, to some extent, tumor heterogeneity [29,31].
An additional way of validating the obtained sources makes use
of the labeling procedure described in [32], to compare the sources
obtained with the mean spectra of tumor and non-tumor regions,
similarly to the Ki-67 threshold validation described above. In
[32], subsets of tumoral and non-tumoral regions were labeled, for
each of the investigated mice, according to the following criteria:
first, the spectra should not correspond to voxels at the edge of the
PRESS-VOI, where signal to noise ratio (SNR) tends to be lower;
and second, as in [33], they had not been collected over, or close
to, the tumor borderline, to avoid as much as possible voxel
‘bleeding’ between tumor/non-tumor regions.
Non-negative Matrix Factorization for Source Extraction
In NMF methods [19,20], the data matrix V (of dimensions
d|n, where d is the data dimensionality and n is the number of
observations), is approximately factorized into two non-negative
matrices, the matrix of sources or data basis W (of dimensions
d|k, where k is the number of sources, and kvd) and the mixing
matrix H (of dimensions k|n, each of whose columns provides
the encoding of a data point: the spectrum of a voxel in this study).
The product of these two matrices provides a good approximation
to the original data matrix, in the form:
V&WH ð1Þ
In this study, the following NMF methods, which cover a wide
palette of algorithmic alternatives, were considered:
N Euclidean distance update algorithm (herein referred to as euc)
[20]. The objective function is optimized with multiplicative
update rules for W and H:
W/W
VHT
WHHT
; H/H
WTV
WTWH
Monotonic convergence of the algorithm can be proven [20].
These update equations preserve the nonnegativity of Wand H,
and constrain the columns of W to sum to unity.
N Alternating least squares (als) [19]. This technique alternately
fixes one matrix and updates the other.
W/ argminW§0 f (W ,H); H/ argminH§0 f (W ,H);
where Wand H are updated as follows:
W/((HHT ){1HVT )T ; H/(WTW ){1WTV
setting all negative elements in Wand H to zero.
N Alternating non-negative least squares using projected gradi-
ents (alspg) [34]. The equations for Wand H in the alternating
least squares method above are solved here using projected
gradients. For H this entails:
N H/P½H{a+f (H); where a is the step size; and P½: is a
bounding function that ensures that the solution remains
within the boundaries of feasibility. The gradient function is
computed as +f (H)~WT (WH{V ). The same approach is
used to calculate W .
N Alternating least squares with Optimal Brain Surgeon (OBS)
[35] (alsobs) [36]. Similar to alternating least squares, this
algorithm alternately solves the least squares equations for
Wand H. The negative elements in Wand H are set to zero
and the rest are adjusted using the OBS method, through
second-order derivatives. The update rules for Wand H are:
W/((HHT ){1HVT )TzdW , and H/(WTW )
{1WTVzdH ;
where dW and dH act as regularization terms and are responsible
for eliminating the less important elements of Wand H ,
respectively (the original OBS was used as a weight pruning
mechanism in artificial neural networks), thus re-adjusting the
Figure 1. Peak maps of principal metabolites for mouse C69, harboring a glioblastoma. It was scanned at 7 Tesla by PRESS-MRSI with
136 ms echo-time. MRSI data were acquired with Bruker ParaVision 4.0, and Fourier interpolated to 32632 voxels, with a final PRESS MRSI data grid of
10610 voxels. Line broadening adjustments and zero order phase correction were carried out. Then, the data were fed into a home-built module for
MRSI post-processing, where the 4.5–0 ppm region of each spectrum was individually normalized to Unit Length (UL2). Each map shows the peak
height in absolute values of the studied metabolite in each voxel. The white dotted lines highlight the tumoral mass according to T2-W MR images.
The scales reflected in the colors coding are in arbitrary units.
doi:10.1371/journal.pone.0047824.g001
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remaining elements optimally. More implementation details can
be found in [37].
N Convex-NMF [18]. To achieve interpretability, this method
imposes a constraint that the vectors (columns) defining W
must lie within the column space of V , i.e. W~VA (where A
is an auxiliary adaptive weight matrix that fully determines
W ), so that V&VAH. Unlike the previous ones, this NMF
variant applies to both nonnegative and mixed-sign data
matrices. It allows also the sources in W to be of mixed-sign,
while the mixing coefficients in H are nonnegative. The factors
H and A are updated as follows:
HT/HT
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(VTV)zAzHTAT (VTV ){A
(VTV){AzHTAT (VTV )zA
s
,
A/A
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(VTV )zHTz(VTV ){AHHT
(VTV ){HTz(VTV )zAHHT
s
where (:)z is the positive part of the matrix, where all negative
values become zeros; and (:){ is the negative part of the matrix,
where all positive values become zeros.
N We reckon Convex-NMF to be especially well suited to the
analysis of MRS data for the following two reasons:
N Firstly, and as just mentioned, because it relaxes the constraints
of non-negativity both in the matrix of observed data and in
the extracted sources. The analyzed MR spectra include
negative peaks, so that we would expect the extracted sources
to contain negative values as well. The absolute values of the
spectra were used when applying NMF methods other than
Convex-NMF. As a result, negative peaks such as the inverted
lactate peak are not lost (as they would be if the signal was
truncated). In any case, Convex-NMF does not require any ad
hoc distortion of the observed signal.
N Secondly, because, by restricting W to convex combinations of
the columns of V we can, in fact, understand each of the basis
or sources as weighted sums of data points (given that
W~VA). This is a unique feature of Convex-NMF that
brings about an interesting result: sources can, to some extent,
be considered as cluster centroids or, more abstractly, as
representatives or prototypes of the groupings in which the observed
data are naturally structured. As shown in [18], the results of
Convex-NMF, if seen as an unsupervised clustering procedure,
often agree with those provided by the well-known K-means
algorithm [38]. In fact, it is proved in [18] that Convex-NMF
is a relaxation of the K-means algorithm. Interestingly,
Convex-NMF is bound to generate sparse mixing matrices
H (with many elements taking values close to zero), which are
practical as cluster indicators. As a result of all this, the sources
obtained by Convex-NMF are likely to be interpretable and
similar to data group centroids.
Experiments with the different NMF methods were carried out
to identify which of them yielded better results in terms of the
correlation between the sources and the average spectra of the
tumor and non-tumor areas of each mouse. These average spectra
for each mouse were taken from the subsets of voxels labeled as
tumor and non-tumor, as described in the previous section.
NMF Initialization
NMF methods unavoidably converge to local minima. As a
result, the extracted NMF bases might be different for different
initializations. In this study, six initialization methods were
investigated, covering a wide array of approaches: from random
initialization, to prototype-based clustering methods such as K-
means and Fuzzy C-Means (FCM), which provide a data density-
based sample of initial data locations; and to feature extraction
techniques such as Principal Component Analysis (PCA), Inde-
pendent Component Analysis (ICA) and NMF itself, which
initialize the algorithm according to the basic eigenstructure of
the data.
All the NMF algorithms, for all initializations, were allowed to
achieve convergence. Convergence was qualified as the lack of
variation in the reconstruction error, from one iteration to the
next, over a common set small threshold of value 1025.
Voxel Labeling using the Mixing Matrix and the Sources
As explained in the introduction, NMF in this study is used as
an unsupervised method in the sense that the labels of MRSI
voxels are not used to create the data model. The obvious
advantage of this approach lies in the fact that the labeling
procedure becomes independent of the availability of labeled
MRSI datasets. Two further advantages come with this indepen-
dence: First, the generalization capabilities of the obtained model
will not be compromised by the bias introduced by the finite size of
the labeled sample. Second, the negative effect of mislabeled cases
on the generalization capabilities of the model will be prevented.
In order to represent the data using the source signals obtained
through the chosen NMF method, we propose to infer the labels of
each voxel only on the basis of the mixing matrix and the
calculated source signals. The contribution of each source is
estimated by calculating the scalar product between the original
voxel spectrum and the reconstructed component of the voxel
spectrum that is obtained from one individual source and the
corresponding mixing matrix element (i.e. loading) for that voxel.
The contribution C of source k (from K sources) to voxel i (from
N voxels) is then given by:
Ci,k~V
T
i WkHk,i, i~1:::N, k~1:::K ð2Þ
The predicted label can then be inferred from the values in C as
follows: for each voxel i, the label li is provided by the source k
that has the highest value of contribution for that voxel, that is
li~ argmaxfkg (Ci,k).
Experimental Settings
For each mouse, the data matrix V is built with the available
MRSI spectra. Its dimension is 6926100 (corresponding to 692
frequencies in the spectral interval of interest, between 0 and
4.5 ppm, and 100 voxels). All the investigated variants of the NMF
method, with all considered initialization strategies, were used to
calculate the underlying source signals. The interpretation of each
source was made by reference to the average spectra of the
corresponding mouse brain regions, as previously mentioned. The
method was set up to calculate two source signals, under the
hypothesis that one of them will represent the tumor, while the
other will represent the non-tumor region. This is intended to
capture the separation between the two main tissue types.
After calculating the source signals and the mixing matrix,
binary (tumor vs. non-tumor) labels for each voxel were then
generated in a fully unsupervised mode. The correlations between
Convex-NMF for Brain Tumor Delimitation
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the spectra in each voxel and each source were calculated, and the
label was assigned according to the source that yielded the highest
correlation. If the correlation between the spectrum of a voxel and
both sources was below a threshold of 50%, then we labeled this
voxel as ‘undecided’ (thus effectively abstaining from labeling the
voxel). Assigning a color for each source, and black for the
‘undecided’ voxels, we created color maps with the labels, that we
call ‘‘source-based labels maps’’.
As an alternative form of representation, we used the
contribution values of only the tumor source to each voxel, from
Eq.2, obtained as described in the previous section. Color maps
were created using these values, with hues of red representing the
highest contribution values, which correspond to voxels labeled as
tumor, and hues of blue representing the lowest contributions,
which correspond to non-tumor. The darkest hue of red
corresponds to the highest absolute contribution of the tumor
source and darkest blue corresponds to the lowest one. We call
these maps ‘‘source contributions maps’’.
Results
A. Source Signals
For illustration, tables 1 and 2 show the correlations obtained
between the sources (obtained with the five NMF methods
previously described, each with the six different initialization
strategies proposed) and the corresponding average spectra of
tumor and non-tumor areas, at LTE and STE, respectively, for
one of the seven mice, namely C69. The correlation values
obtained for the remaining six mice are compiled in tables S1 and
S2. Mouse C278 practically does not contain non-tumor area that
fulfils the selection criteria outlined in the Material and Methods
section. Thus, only a fraction of the voxels was labeled as tumor
whereas the rest were labeled as ‘‘other’’. Therefore, for this mouse
in particular, we only made the comparison between the average
spectrum of the tumor area and the tumoral source in tables S1
and S2.
Convex-NMF yields, overall and consistently, the best correla-
tion results. The results are also fairly insensitive to the
initialization strategy. The source signals calculated in the
experiments carried out with all mice at LTE and STE, using
Convex-NMF with K-means initialization, are displayed in
figures 2 and 3, respectively. In K-means clustering, H was
initialized as H (0)~Pz0:2E, where E is a matrix of all its
elements equal to one, and P~(pi; :::pn) was filled with the cluster
indicators, which are based on the cluster indices of each point,
such that Pik~f0; 1g, where the ones indicate cluster member-
ship. A was initialized as A(0)~(Pz0:2E)D{1, where D is a
diagonal matrix with each element being the number of points in
each cluster [18].
In order to visualize the similarities and differences of the
calculated sources with respect to the average spectra of areas
labeled by the expert as tumor and non-tumor, we superimposed
the calculated sources to the average spectra, and to the set of all
labeled spectra, as shown in figures 2 and 3. The sources on the
left hand side column have a clear pathological profile, as
expressed by the presence of high choline, lactate and mobile lipid
peaks and low or no NAA [27,39]. Instead, the sources on the
right hand side column mostly represent non-tumor tissue. These
results are consistent with some of the Convex-NMF properties
described in previous sections: as stated there, the sources obtained
by this method are likely to be interpretable and similar to data
group centroids, given that each source is a weighted sum of
spectra, and given the relation between Convex-NMF and the K-
means clustering algorithm.
Figure 4 shows detailed correlation (top row) and Root Mean
Squared Error (RMSE, bottom row) results for all the analyzed
mice at both echo times, where sources were obtained using
Convex-NMF with K-means initialization. These results include
both tumor (darker bars) and non-tumor tissue (lighter bars).
There is some controversy regarding the uniqueness of the
solutions obtained by NMF methods. In order to clarify this for
our results, we took one of the studied mice, namely C69 at LTE,
and compared the sources obtained starting from 50 random
initializations with values in the interval (0,1). Allowing for trivial
permutations in the order in which the sources were obtained by
the Convex-NMF algorithm, the results were consistently 0.99 or
better correlated with the sources. According to this, Convex-
NMF is converging to very similar solutions, which from the
standpoint of the current study could be considered as they are all
one and the same solution.
Secondly, we perturbed the mixing matrix obtained for this class
pair, by multiplication with a random matrix with positive
elements in the range (0,1). This was used to re-initialize the
Convex-NMF algorithm, which converged back to the original
solutions, with a very small difference (0.041560.02 root mean
squared error between the original and the new values). The
results of this second test reinforce our previous statement
regarding the uniqueness of the solutions obtained by Convex-
NMF for the type of data under analysis.
Table 1. Correlations between the sources and the average
spectra for mouse C69 at LTE.
Mouse C69
init euc als alspg alsobs convex
Random .976/.940 .977/.938 .975/.928 .976/.939 .991/.986
K-means .975/.941 .977/.938 .976/.939 .976/.939 .987/.993
FCM .975/.940 .977/.938 .976/.939 .976/.939 .987/.993
PCA .934/.879 .977/.938 .976/.938 .976/.939 .982/.988
ICA .969/.800 .977/.938 .976/.938 .976/.939 .986/.992
NMF .976/.938 .977/.938 .976/.939 .976/.939 .986/.992
Table cells should be read as the correlations between the sources and the
average spectra (see figures 2 and 3) of the tumor/non-tumor areas. The results
of the best performing method, for each initialization condition, are highlighted
in bold.
doi:10.1371/journal.pone.0047824.t001
Table 2. Correlations between the sources and the average
spectra for mouse C69 at STE.
Mouse C69
init euc als alspg alsobs convex
Random .957/.989 .967/.991 .902/.990 .967/.991 .981/.983
K-means .968/.990 .967/.991 .968/.991 .968/.991 .985/.992
FCM .965/.990 .967/.991 .968/.991 .968/.991 .986/.997
PCA .915/.811 .967/.991 .969/.991 .968/.991 .983/.996
ICA .809/.990 .967/.991 .962/.991 .967/.991 .983/.997
NMF .968/.991 .967/.991 .968/.991 .968/.991 .984/.998
Table cells should be read as in table 1.
doi:10.1371/journal.pone.0047824.t002
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B. Voxel Labeling and Tumor Delimitation
Figure 5 shows the T2-W image for one of the studied mice
(C69), together with the respective histology superimposed, using
monoclonal antibody against Ki67, and Ki67 PI maps for voxels
with PI#5% and PI.30%. The yellow squares delimit the VOI
region. The VOI of the same mouse is further detailed in figure 6,
enlarged and overlaid with the 10610 MRSI spectral matrix at
Figure 2. Sources obtained for the seven mice at LTE. The
calculated sources are shown in black color, the average spectra in red,
and all the labeled spectra in gray. The sources in the left column
represent the tumor, and the ones in the right column mainly represent
non-tumoral tissue. Frequencies in the horizontal axis are measured in
ppm.
doi:10.1371/journal.pone.0047824.g002
Figure 3. Sources obtained for the seven mice at STE. The
calculated sources are shown in black color, the average spectra in red,
and all the labeled spectra in gray. The sources in the left column
represent the tumor, and the ones in the right column mainly represent
non-tumoral tissue. Frequencies in the horizontal axis are measured in
ppm.
doi:10.1371/journal.pone.0047824.g003
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LTE. The areas delimited by red and blue lines correspond to
characteristic tumor and non-tumor labels, respectively, labeled as
in [32]. These labels will be referred to, later on in the study, as
‘‘supervised’’. The yellow dotted line in figure 6 delineates the
‘‘radiological anomaly region’’ as judged from the mass shown in
the T2-W image.
The source-based labels maps generated for mouse C69 at LTE
and STE are shown in figure 7. In this figure we superimposed
these maps to T2-W images, to verify the correspondence between
the tumor areas described by the sources and the T2-W image.
There is a single black voxel in figure 7 (source-based labels map
generated for C69 at LTE). This voxel is labeled as ‘undecided’,
indicating that the correlations of the sources with the original
spectrum of this voxel (same position in figure 6: poor SNR), are
under the 50% threshold.
We illustrate the tumor delimitation capabilities of the method
proposed in this paper in figure 8. This figure shows the source
contributions maps generated for the VOI regions of mouse C69
at LTE and STE. The first row shows the 10610 grid of voxels,
with the corresponding color according to the values of C
calculated from Eq.2 for the source representing the tumor in each
voxel. As in figure 7, this is then superimposed over the T2-W
image to verify the high correspondence between the area of the
tumor in both images (the source contributions map and the T2-
W). The maps displayed in the bottom row are created with a
linear interpolation of the maps in the top row, also superimposed
over the corresponding T2-W image.
Figure 9 summarizes the information for the remaining 6 mice
(C71, C32, C179, C233, C234, and C278). The first four rows
contain the known information about these mice, used here to
assess the accuracy of the obtained results, which are compiled in
the last four rows. An additional color, magenta, is used in order to
represent the area that is not normal brain, but neither is being
represented by the main tumoral source (mouse C278, rows 6 and
8).
To determine the extent to which the source-based labels maps
were related to the Ki67 maps, we calculated the accuracy of the
former as compared to Ki67 PI maps for the tumor region (results
for all mice, at LTE and STE, are compiled in table 3). For this, as
described in methods, we considered PI.30% to be a safe
threshold for the solid tumor region, and PI#5% as the threshold
for non-tumor, our ‘‘gold standards’’ according to the opinion of
the expert pathologist. We also calculated the accuracy of the
obtained source-based labels maps in relation to the supervised
tumor and non-tumor labels, described in [32] and shown in
figure 6 for mouse C69. Table 4 contains the results.
Table 5 compiles the sensitivity (true positive rate,
TP=(TPzFN), where true positive (TP) cases are tumor voxels
correctly labeled as tumors, and false negative (FN ) cases are non-
tumor voxels labeled as tumors) and specificity true negative rate,
TN=(TNzFP), where true negative (TN) cases are non-tumor
voxels correctly identified as non-tumors, and false positive (FP)
cases are tumor voxels labeled as non-tumors) of the obtained
source-based labels maps.
In most cases the tumor sources overlapped relatively well the
PI.30% (table 5 and figures 7, and 9), but there were some
exceptions. In mouse C69, there was a spread of the tumor source
outside the mass as seen on MRI towards the caudal part of the
brain. In mouse C179 the source spread towards the smaller mass,
which had been labeled as less than 30% PI by the Definiens
coregistration.
In both cases, an additional manual sampling and count of
0.1 mm2 squares along the vertical and horizontal axes of the
tumor (figures 10 and 11) revealed that:
In mouse C69 the tumor was well delimited, lacking surround-
ing infiltrative areas. However, the bottom (caudal) edge of the
tumor, presented an area with a PI of 13% due to proliferating
glial cells in the Cornu Ammonis (CA) of the hippocampus. Despite
this, the top (rostral), right and left immediately adjacent to the
tumor areas had a PI of 0, 5.4, and 3.3% respectively, consistent
with a well delimited tumor mass and the ,5% threshold for non-
tumor set before. These results may explain the spread of the
source of the tumoral area observed outside the caudal T2-W
anomaly region (figure 7). Additionally, the mean of samplings
performed inside the tumor mass yielded a PI of 73.9% and
cellularity of 3647 cells/mm2 (2251 proliferating cells/mm2),
consistent with a similar study (ca. 2000 proliferating cells/mm2),
reported in [40].
Figure 4. Correlations and errors. Correlations (top row) and errors (bottom row) between the source signals and the average spectra of the
labeled areas (as measured by RMSE). Dark gray bars: tumors; light gray bars: non-tumor tissue.
doi:10.1371/journal.pone.0047824.g004
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Regarding mouse C179 in which two masses are evident on
the MRI (figure 9) both T2-W and source based maps
recognize tumor better than our self-imposed ‘‘gold standard’’
(PI.30%). In this respect, figure 11 shows a transition area of
proliferating cells, between the big and the small mass. The two
samplings in the transition area showed PI values of 24.5 and
21.5% and the third sampling, already in the smaller mass, had
a PI of 40%. These values are consistent with the .30% PI for
solid tumor and above the 5% PI for normal brain, and agree
both with the T2-W and the source maps at both echo times. A
Figure 5. Histology information of mouse C69. T2-W image (top left); Ki67 immunostained digitized slide (top right); Ki67 map with PI#5%
(bottom left); and Ki67 map with PI.30% (bottom right), of mouse C69, bearing a GL261 GBM tumor. The last two maps are superimposed on the
corresponding reference T2-W image. Color columns at the bottom show PI scale.
doi:10.1371/journal.pone.0047824.g005
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possible explanation for this disagreement between the values
provided by the automated coregistration method and the MRI
and the MRSI can be that an affine was applied instead of an
elastic transformation.
It should also be kept in mind that the size of the MRSI coded
pixels (0.5560.55 mm in plane resolution and 1 mm slice
thickness in the 3rd dimension) [27] leads to partial volume effects,
causing most borderline pixels to contain PI contributions from
both tumor and non-tumor regions and artificially increasing (or
decreasing) the average PI. These may explain as well why,
particularly in mice C32 and C234, the source maps are smaller
than the T2-W image (figure 12). Histopathology slides for these
two mice were also manually checked and for example, in mouse
C32, the PI for the periphery was comprised in the 58.5–76.9%
range.
No accuracy/sensitivity/specificity calculation has been per-
formed for the borderline pixels or for Ki67 regions between 5 and
30% Ki67 because of the confluence of several problems. Namely,
1) restricted MRSI resolution (0.5560.5561 mm) compared with
the MRI resolution (0.1560.1561 mm), 2) imperfect registration
of in vivo and ex vivo histopathology data, and 3) self-imposed
restriction of the number of sources to be used to two in this initial
discrimination study of tumor and non-tumor regions. Still, we
have attempted an approximation to a full account of the acquired
VOI with respect to its tumor/non-tumor recognition, and for this
the gold standard threshold for tumor has been maintained at
.30% while all regions with PI below 30% have been combined
into the ‘‘non-tumor’’ label. This has produced the results shown
in figure 12 and table 6.
An interesting result is that comparison with Ki67 maps
yields in all cases lower sensitivity and specificity (table 6) than
comparison with the supervised labels (table 5). This also
happens when correlation is calculated (table 3 vs. table 4). This
is probably caused by the already mentioned effect of taking all
voxels (including borderline pixels) in the calculation when
analyzing images, while the supervised labeled images do not
Figure 6. VOI region of mouse C69. T2-W image enlarged and overlaid with the MRSI matrix at LTE; spectra shown in white. The red and blue
contours delineate, in turn, characteristic tumor and non-tumor areas used for calculating the average spectra to which the unsupervised sources
were compared. The yellow dotted line outlines the tumor as judged from the ‘‘anomaly region’’ on the reference T2-W image. Bottom spectra 1 and
2 arise, enlarged, from the voxels labeled in the top image.
doi:10.1371/journal.pone.0047824.g006
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take into account borderline pixels between tumor and non-
tumor tissue, as well as the specific coregistration algorithm
used.
The borderline regions of the tumors according to the T2-W
image are heterogeneous and contain regions of anomaly which
the source maps incorporate into either tumor (mostly in mice
C69, C179 and C278) or non-tumor regions (mostly in mice C32,
C233 and C234), depending of the mouse analyzed, thus
providing a different delimitation of the abnormal mass which
may be relevant for its evaluation and follow-up.
Discussion
A. Source Signals
The results reported in tables 1, 2, S1 and S2 indicate that NMF
methods are capable of extracting tissue type-specific (tumor or
non-tumor) sources. In terms of correlation, Convex-NMF
outperforms the other methods tested, with small differences for
different initialization strategies. The higher correlations provided
by Convex-NMF are very noticeable for non-tumor tissue,
especially at LTE, for most mice. In some cases, the initialization
results yielded by PCA and ICA are very good, e.g. C71 (at LTE
and STE) and C32 (at LTE), but very poor in others, e.g. C179 (at
LTE), becoming much worse than random. K-means and FCM
initializations yielded very similar results, except in some cases in
which FCM performed worse, e.g. C179 (at LTE and STE). The
combination of Convex-NMF and K-means initialization was the
most stable of all, providing very good correlation results.
In a previous study [41], where we assessed the abilities of two
variants of ICA [42,43], namely JADE [44] and FastICA [45], to
identify the constituent tissue types in single-voxel MRS, ICA
showed no advantages over NMF methods.
With respect to the acquisition conditions, both TE sources
seem to perform similarly in average (tables 3, 4, 5, 6) for
delineating tumor and normal tissue, with quantitative variations
depending on the specific mouse studied (table 6 and figure 12),
but see next section for further comments on this.
The results in figures 2 and 3 support our initial assumption that
the two main sources obtained by Convex-NMF correspond to
tumor and non-tumor tissues.
GBM are highly malignant, WHO grade IV tumors [46],
usually showing a strong mobile lipid MRS signal (at ca. 1.3ppm),
most evident at STE [47] (see figure 3, left column). Normal brain
tissue is usually characterized by a clear NAA peak at 2.02ppm
with similar height to creatine (3.03ppm) and choline-containing
compound (3.21 ppm) peaks in mice models [39]. In the tumor
area, the creatine peak height decreases, while the total choline
peak increases. Lactate (1.3ppm) resonances appear inverted at
LTE (see figure 2, left column) but overlap lipid signals at STE (see
figure 3, left column).
B. Voxel Labeling and Tumor Delimitation
The red area obtained for both source-based labels maps in
figure 7 corresponds to the tumoral area previously delimited and
to the true proliferative tumor area, as shown by the Ki67 images
(figure 5). This similarity has been achieved using our proposed
method to generate source-based labels maps in a fully unsuper-
vised way. Previous approaches for brain tumor segmentation
based on MRS labeling, such as [48], are all supervised. This
unsupervised approach would allow us to provide a labeling
prediction independent of the availability of a labeled data set.
The source-based labels maps have been the type of maps
chosen for detailed quantitative evaluation of the outcome of the
proposed approach (tables 3, 4, 5, 6 and figure 12). Still, the use of
the source contributions maps (figures 8, 9) may have advantages
in future studies to better sample tissue transition zones or when
more than two sources need to be considered.
While most of the existing unsupervised strategies are based on
MRI, the area of metabolic abnormality for human brain tumors
is usually larger than the area delimited by conventional MRI
Figure 7. Source-based labels maps generated for mouse C69. The maps obtained at LTE (left) and STE (right) are superimposed to the T2-W
reference image. The red color identifies tumor (T), blue identifies non-tumor (N), and black represents ‘undecided’. The color intensities shown in the
scale bar on the right hand side correspond to the magnitude of the correlation values between the spectra of the voxels and their representing
source. The yellow dotted lines outline the tumor region, as judged from the T2-W image, similar to figure 6.
doi:10.1371/journal.pone.0047824.g007
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[49]. This may lead, e.g., to inaccuracies in the evaluation of
therapy response volumes.
Previous work [23] applying NMF to MRSI data of patholog-
ical states, either on acute or chronic phases, yielded a recovered
abnormal image beyond the regions of abnormal signal intensity
on T2-W Fluid Attenuated Inversion Recovery (FLAIR) images
(T2-W with flowing liquid attenuation) [50], whose match was
evaluated only visually. While correctly mapping the abnormal-
ities, our approach provides a good delineation of the abnormal
area and quantitative estimates of the prediction accuracy. In
addition, since we applied Convex-NMF to a preclinical model
rather than to human patients, there is an authentic biological
correlate of the true proliferative tumor area, as shown by the
histopathology co-localized images (figures 5, 9 and 12). Our
results match well the tumoral area (figure 12 and table 6), with the
limitations already pointed out in the results section and discussed
below.
Despite a particular mouse (C179), the remaining six mice
studied showed a clearly circumscribed tumoral mass, essentially
with minor or no infiltration outside the tumor. Mouse C69,
already discussed, had a tumoral source that extended over MRI-
normal areas of the brain in its caudal part (figure 10), which
corresponded to PI = 13%. In fact, Ki67 positive cells detected
outside the tumor mass in this caudal part were not tumoral, but
glial cells (morphologically identified by the pathologist). In this
respect, it has been described that proliferative reactive astrocytes
(astrogliosis) are attracted to brain tumors [51]. Anatomically, this
was observed in the hippocampus region, which is also known to
contain proliferating neural stem cells (NSC) [52]. Indeed,
increased proliferation of NSC and tropism towards GL261
GBM has been demonstrated [53]. A combination of these facts
Figure 8. Source contributions maps representing the tumor area of mouse C69. They codify the C values of Eq.2 scaled between 0 and
100. The maps obtained at LTE (left column) and STE (right column) are superimposed over the T2-W reference image. The red color identifies the
tumor, while blue identifies non-tumoral tissue. The yellow dotted lines outline the tumor region, as judged from the T2-W image, similar to figure 6.
Top row: 10610 grid of voxels. Bottom row: the same map interpolated. Color columns on the right hand side of the maps indicate C scale in
percentage.
doi:10.1371/journal.pone.0047824.g008
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may explain that source analysis recognized this as abnormal
region (tumor plus astrogliosis).
Concerning the non-tumor area of mouse C179, data shown in
figures 9, 11 and 12, and in tables 3 and 4, suggest that the sub-
optimal agreement of source-derived maps (especially at STE) and
Figure 9. Summary of the results for mice C71, C32, C179, C233, C234, and C278. T2-W images (first row), Ki67 slides (second row), Ki67
maps with PI#5% (third row), Ki67 maps with PI.30% (fourth row), source contributions maps (interpolated) of the tumoral source calculated at LTE
(fifth row), and STE (seventh row), source-based labels maps calculated at LTE (sixth row) and STE (eighth row). Color columns of rows 3 and 4 as in
figure 5. Color columns of rows 5 and 7 as in figure 8. Color columns of rows 6 and 8 similar to figure 7, adding a new color (magenta) to represent
the region below the main tumor source 50% threshold (O, ‘‘other’’) in mouse C278. Please note that C278 does not contain non-tumoral tissue
voxels that fulfill the labeling criteria for source calculation according to [32,33].
doi:10.1371/journal.pone.0047824.g009
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Ki67 maps may have its origin in the existence of two masses,
instead of just one. This will produce a higher percentage of
borderline voxels and, accordingly, a higher partial volume effect.
Furthermore, in this particular instance, both T2-W and source
based maps recognize tumor better than our self-imposed ‘‘gold
standard’’ (PI.30%). This may be caused in this case by labeling
‘‘dilution’’ when considering the decreased MRSI-like resolution
used in the Ki67 grid. In this respect, figure 11, shows a borderline
area for the C179 small mass which did already provide a manual
PI count (40%) clearly above the tumor ‘‘threshold’’, also in
agreement with the T2-W and source map result.
Furthermore, in mouse C278 the source for tumor delimits a
clearly smaller area than the abnormal brain mass. This was
because in this case lacking a proper normal brain area two
sources were sought and the results on tables 3, 4, 5, 6, are
calculated only according to one of the sources (the most
correlated with tumor). In this case, the appropriate could have
been to combine the regions produced by the two sources, but
we decided to only keep the most correlated one, as for the other
six mice, for calculations. Finally, when comparing the T2-W
images with the Ki67 maps and the source-based labels maps
with the Ki67 maps (table 6 and figure 12), sensitivity was higher
for T2-W than for the source maps (particularly due to mice
C32, C233, C234 and C278 for the above-discussed reasons). In
contrast, specificity was similar for the T2-W area and the
source-based labels maps. In mouse C179 the metabolic
abnormality area is clearly underestimated by the Ki67 map,
which has already been discussed, and it is for this reason that
specificity is so low.
When borderline pixels are considered we must recognize that
there are some mismatches, both for the T2-W images and for the
maps of the sources with respect to the ‘‘gold standard’’ PI map
from histopathology. In some cases the source-based map covers a
smaller region than the ‘‘gold standard’’ while in other cases it
covers a larger area. The MRI-based T2-W image provides an
overall similar rendering to the source map when recognizing non-
tumor (specificity average values 0.78 vs. 0.77 and 0.78) while
being slightly better when categorizing tumor (sensitivity average
values 0.99 vs. 0.84 and 0.83). Still, these mismatches have to be
taken with due perspective. In short, the metabolomic map
provided by the sources may be seeing in some cases different
information than the other T2-W in vivo map. The major reason
for this slight underestimation of the abnormal region in some
cases, specifically C32 and C234 al LTE, may be the restricted
resolution of MRSI as compared to MRI data. On the other hand,
recognition of metabolomic abnormality seems better using
sources for C69, C179 and C278, but for different reasons in
each case (caudal tail non-tumoral cells proliferation, PI close to
threshold, VOI too small for the tumor size).
A possible criticism to our approach is the limitation of the
automated Ki67 maps, and the need to perform additional manual
counts to counter-check for discrepant PI values with respect to the
sources obtained. However, coregistration of whole mouse brain
with MRI/MRSI is not a straightforward task, first of all because
the minor deformation suffered by the sample upon dehydration
and the paraffin embedding processes and second for the lack of
available software. Possible future improvements in the coregistra-
tion could imply using elastic transformations, but at the time
Table 3. Relationship between the Ki67 maps and the
source-based labels maps.
LTE STE
Mouse T N T N
C69 100(41/41) 93.3(28/30) 97.6(40/41) 86.7(26/30)
C71 91.9(57/62) 91.7(22/24) 83.9(52/62) 91.7(22/24)
C32 66.7(38/57) 100(10/10) 84.2(48/57) 100(10/10)
C179 100(33/33) 66.7(16/24) 66.7(22/33) 37.5(9/24)
C233 86.7(52/60) 100(16/16) 91.7(55/60) 100(16/16)
C234 69.8(44/63) 100(10/10) 87.3(55/63) 100(10/10)
C278 71.1(54/76) – 71.1(54/76) –
Mean 83.7 92.0 83.2 86.0
T stands for the accuracy between a PI.30% and the tumor area delineated by
the source-based labels maps; while N stands for the accuracy between a
PI#5% and the corresponding non-tumor area. The numbers in parentheses
correspond to the number of correctly labeled voxels from the total. The last
row contains the mean values for each column.
doi:10.1371/journal.pone.0047824.t003
Table 4. Relationship between the supervised labels and the
source-based labels maps.
LTE STE
Mouse T N T N
C69 100(17/17) 100(14/14) 100(17/17) 100(14/14)
C71 100(26/26) 100(7/7) 100(26/26) 100(7/7)
C32 91.7(22/24) 100(10/10) 100(24/24) 100(10/10)
C179 100(9/9) 100(9/9) 88.9(8/9) 66.7(6/9)
C233 100(29/29) 100(12/12) 100(29/29) 100(12/12)
C234 84.4(27/32) 100(5/5) 100(32/32) 100(5/5)
C278 87.5(35/40) – 92.5(37/40) –
Mean 94.8 100 97.3 94.5
T stands for the accuracy between the supervised tumor labels (as in figure 6)
and the tumor area delineated by the source-based labels maps; while N stands
for the accuracy between the non-tumor labels and the corresponding non-
tumor area. The numbers in parentheses correspond to the number of correctly
labeled voxels from the total. The last row contains the mean values for each
column.
doi:10.1371/journal.pone.0047824.t004
Table 5. Sensitivity and specificity for the source-based labels
maps.
LTE STE
Mouse Ki67 Supervised Ki67 Supervised
C69 1.00/0.93 1.00/1.00 0.98/0.87 1.00/1.00
C71 0.92/0.92 1.00/1.00 0.84/0.92 1.00/1.00
C32 0.67/0.46 0.92/1.00 0.84/1.00 1.00/1.00
C179 1.00/0.50 1.00/1.00 0.67/0.38 0.89/0.86
C233 0.87/0.48 1.00/1.00 0.92/1.00 1.00/1.00
C234 0.70/0.47 0.84/1.00 0.87/1.00 1.00/1.00
C278 0.71/2 0.88/2 0.71/2 0.93/2
Mean 0.84/0.63 0.95/1.0 0.83/0.86 0.97/0.98
Sensitivity and specificity (sensitivity/specificity) calculated for the source-based
labels maps with respect to the Ki67 maps (columns named as Ki67, computed
as in table 3), and the supervised labels provided (columns named as
‘Supervised’, computed as in table 4), for each mouse, at LTE and STE. The last
row contains the mean values for each column.
doi:10.1371/journal.pone.0047824.t005
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when we started this study, we could not foresee this problem
which we overcome resorting to manual cell counts based in
anatomical references. Note as well that our histology sections
were 3 mm thick while the MRSI VOI slice width was 1 mm, and
the diameter of a tumor cell is around 10–20 mm, hence another
complicating factor. The specific histology slide was chosen by the
pathologist based again on pure anatomical criteria.
Other, perhaps simpler, approaches would also be feasible for
brain tumors, such as the CNI index (essentially a choline/NAA
ratio normalized to the normal contralateral brain ratio). In [16],
cancer was predicted with 86% specificity and 90% sensitivity
using a CNI threshold of 2.5, but, due to technical and ethical
limitations, only selected target regions obtained by image-guided
surgery could be evaluated by comparison with the histopathology
gold standard - this was not the case in our preclinical study. In
our case specificity, when considering selected target regions
(supervised labels), was 100% for LTE maps; sensitivity was 100%
for 4/7 mice and between 84–92% in the remaining 3/7 mice
Figure 10. Ki67 preparation from mouse C69. On the left hand side, 0.1 mm2 manual sampling areas (colored rectangles) for positive Ki67 cells’
evaluation (brown spots): black squares, sampling inside the tumor mass; blue squares, samplings adjacent to tumor mass; red squares, Cornu
Ammonis samplings adjacent to tumor mass, shown enlarged on the right. On the right hand side, rectangles from top to bottom: PI was 57, 13 and
13.3%; the first square was inside the tumor mass, the second one was adjacent to it, and the third one was outside the tumor. Cellularity was 5100,
1200 and 750 cells/mm2, respectively. Non-proliferating nuclei were stained in blue and proliferating nuclei in brown. The small insert in the right
image (blue square) shows the location of the enlarged image with respect to the whole brain. The white bar at the bottom-right shows scale.
doi:10.1371/journal.pone.0047824.g010
Figure 11. Ki67 preparation from mouse C179. The connecting region between the two tumor masses is shown enlarged, displaying three
0.1 mm2 areas manually sampled. From top (smaller mass) to bottom (main mass), PI: 40%, 21.5%, 24.5%, and 62.7%. White bar at bottom-left corner
shows the scale. The insert at the bottom left corner shows the location of the enlarged image (blue rectangle) with respect to the whole brain.
doi:10.1371/journal.pone.0047824.g011
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(table 5). It may also be worthwhile to point out here that the CNI
index may also show miss-registration with respect to the
abnormal mass region according to MRI. Thus, work by Nelson
et al. [54] did show a much smaller ‘‘metabolic lesion’’ (with a CNI
threshold of 3) area than the overall T2-W ‘‘anomaly region’’ area
in a Glioblastoma patient. Finally, the hyperpolarized lactate/
pyruvate ratio may also provide a handle for tumor/brain
discrimination, both in developing tumor and upon therapy
response [55,56], although the low lactate signal detectable in
normal brain tissue and MRSI resolution issues may also cause
difficulties in defining the border between normal and abnormal
tissue.
Conclusions
The clinical management of human brain tumors is an
important and delicate challenge for radiologists, who have to
make their decisions on the basis of indirect evidence gathered
through non-invasive techniques.
One of the main sources of uncertainty in this context arises
from the difficulty of appropriately delimiting the pathological
area of the brain. In this study, we have provided evidence
supporting that a robust delimitation can be achieved through the
application of blind source extraction techniques to 1H-MRS
multi-voxel data. More specifically, we have proposed and tested a
fully unsupervised methodology that uses Convex-NMF source
extraction to consistently delimitate the tumor region. This
method is successfully benchmarked against alternative NMF
methodologies. The accuracy of tissue delineation was quantified
by comparison with the gold standard of tissue assignment, by
direct histopathological measurements in the tumoral region.
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